The funds will allow the company to continue a Phase I/II trial of its CDK2 inhibitor in certain hard-to-treat biomarker-defined cancers.

NEW YORK – GSK will roll out its anti-PD-1 therapy Jemperli (dostarlimab) for certain endometrial cancer patients and its PARP inhibitor Zejula (niraparib) for ovarian cancer patients in India.

Collaborators from various institutions will leverage the latest multi-disciplinary drug development tools to produce tailored treatment and prevention strategies.

The company is testing its lead asset, a CAR T/NK-cell therapy, in a Phase I trial in patients with B-cell malignancies.

NEW YORK – Kelonia Therapeutics this week said it has started treating patients with relapsed and refractory multiple myeloma in a Phase I trial of its in vivo CAR T-cell therapy KLN-1010.

NEW YORK – Krystal Biotech has discontinued a Phase I/II clinical trial evaluating an injected version of its gene therapy KB707 in locally advanced or metastatic solid tumors, including melanoma.

The antisense oligonucleotide is a prophylactic treatment for preventing swelling attacks due to hereditary angioedema.

A lab's interpretation that an STK11 variant of uncertain significance is likely pathogenic supports a young woman's ...

ALX hopes to gain insights by tracking EGFR expression in a new trial of ALX2004 and to identify best responders using CD47 expression in a trial of evorpacept.